Conmed (CNMD) Tops Q3 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- SpaceX extends losses after $600 billion wipeout, tech stocks slide again
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Leerink Partners Cuts Price Target on Conmed (CNMD) to $43; Reiterates Market Perform
October 28, 2016 9:04 AM EDTLeerink Partners maintained a Market Perform rating on CONMED (NASDAQ: CNMD), and cut the price target to $43.00 (from $47.00), following the company's 3Q earnings report. 3Q revenues of $185M beat $178M estimates, and organic growth of +0.8% beat +0.4% forecasts and marked an improvement vs. -1% in 2Q and -2% in 1Q. Airseal revenues... More
